Gilead Sciences, Inc. has acquired all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition adds clinical development pipeline assets for well-validated targets in oncology and inflammation.   Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Both programs have the potential to address multiple indicati...